AbbVie (XSWX:ABBV) Quality Rank


XSWX:ABBV AbbVie Inc XSWX:ABBV
65 GF Score
Price CHF206.75
GF Value CHF167.66
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is AbbVie Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

AbbVie Quality Rank Related Terms

XSWX:ABBV
65GF Score
AbbVie Inc XSWX:ABBV
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is AbbVie (XSWX:ABBV) Overvalued in 2026?

Based on GuruFocus' analysis, AbbVie stock appears to be overvalued. The current stock price of CHF206.75 is trading 23.3% above its estimated GF Value™ of CHF167.66. GuruFocus considers AbbVie to be Modestly Overvalued.

Key valuation signals for XSWX:ABBV:

  • Quality Rank:
  • GF Value™: CHF167.66 vs. price of CHF206.75 (23.3% above fair value)
  • GF Score™: 65/100 with 4 warning signs

No single metric tells the full story. See the XSWX:ABBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AbbVie Business Description

Address 1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
65GF Score

Get the complete analysis for XSWX:ABBV

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF206.75
Price
CHF167.66
GF Value